StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

Research analysts at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NASDAQ:NURO opened at $4.39 on Monday. The company has a 50-day simple moving average of $4.12 and a 200 day simple moving average of $3.99. The company has a market capitalization of $9.00 million, a P/E ratio of -0.96 and a beta of 2.18. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73.

Institutional Investors Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC bought a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix as of its most recent filing with the SEC. 19.40% of the stock is owned by institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.